32 results on '"Buchanan, Fritz G."'
Search Results
2. Discovery of Potent Azetidine-Benzoxazole MerTK Inhibitors with In Vivo Target Engagement.
3. Discovery of Potent Azetidine-Benzoxazole MerTK Inhibitors with In VivoTarget Engagement
4. Discovery of A-910, a Highly Potent and Orally Bioavailable Dual MerTK/Axl-Selective Tyrosine Kinase Inhibitor
5. Data from ABT-414, an Antibody–Drug Conjugate Targeting a Tumor-Selective EGFR Epitope
6. Figure S1 from Characterization of ABBV-221, a Tumor-Selective EGFR-Targeting Antibody Drug Conjugate
7. Data from Characterization of ABBV-221, a Tumor-Selective EGFR-Targeting Antibody Drug Conjugate
8. Supplementary Table 1, Table 2; Supplementary Figure 1 from ABT-414, an Antibody–Drug Conjugate Targeting a Tumor-Selective EGFR Epitope
9. Supplementary Data from Hexavalent TRAIL Fusion Protein Eftozanermin Alfa Optimally Clusters Apoptosis-Inducing TRAIL Receptors to Induce On-Target Antitumor Activity in Solid Tumors
10. Data from Hexavalent TRAIL Fusion Protein Eftozanermin Alfa Optimally Clusters Apoptosis-Inducing TRAIL Receptors to Induce On-Target Antitumor Activity in Solid Tumors
11. Discovery of a selective catalytic p300/CBP inhibitor that targets lineage-specific tumours
12. Author Correction: Discovery of a selective catalytic p300/CBP inhibitor that targets lineage-specific tumours
13. Corrigendum to “Investigation of biaryl heterocycles as inhibitors of Wee1 kinase” [Bioorg. Med. Chem. Lett. 29 (2019) 1481–1486]
14. Hexavalent TRAIL Fusion Protein Eftozanermin Alfa Optimally Clusters Apoptosis-Inducing TRAIL Receptors to Induce On-Target Antitumor Activity in Solid Tumors
15. Investigation of biaryl heterocycles as inhibitors of Wee1 kinase
16. Utilization of18F-Fluorodeoxyglucose–Positron Emission Tomography To Understand the Mechanism of Nicotinamide Phosphoribosyltransferase Inhibitors In Vivo
17. Reversal of oncogene transformation and suppression of tumor growth by the novel IGF1R kinase inhibitor A-928605
18. Characterization of ABBV-221, a Tumor-Selective EGFR-Targeting Antibody Drug Conjugate
19. Abstract LB-A23: Discovery of a potent catalytic p300/CBP inhibitor that targets lineage-specific tumors
20. Erratum: The EED protein–protein interaction inhibitor A-395 inactivates the PRC2 complex
21. Discovery of a selective catalytic p300/CBP inhibitor that targets lineage-specific tumours
22. The EED protein–protein interaction inhibitor A-395 inactivates the PRC2 complex
23. Abstract 4718: ABBV-075, a novel BET family bromodomain inhibitor, represents a promising therapeutic agent for a broad spectrum of cancer indications
24. ABT-414, an Antibody–Drug Conjugate Targeting a Tumor-Selective EGFR Epitope
25. Utilization of 18F-Fluorodeoxyglucose–Positron Emission Tomography To Understand the Mechanism of Nicotinamide Phosphoribosyltransferase Inhibitors In Vivo▪
26. The Histone Methyltransferase Inhibitor A-366 Uncovers a Role for G9a/GLP in the Epigenetics of Leukemia
27. Characterization of ABT-806, a Humanized Tumor-Specific Anti-EGFR Monoclonal Antibody
28. Abstract 5532: Discovery of A-366, a novel small molecule inhibitor that uncovers an unappreciated role for G9a/GLP in the epigenetics of leukemia
29. Pyrimidine-Based Tricyclic Molecules as Potent and Orally Efficacious Inhibitors of Wee1 Kinase
30. Optimization of Phenyl-Substituted Benzimidazole Carboxamide Poly(ADP-Ribose) Polymerase Inhibitors: Identification of (S)-2-(2-Fluoro-4-(pyrrolidin-2-yl)phenyl)-1H-benzimidazole-4-carboxamide (A-966492), a Highly Potent and Efficacious Inhibitor
31. Reversal of oncogene transformation and suppression of tumor growth by the novel IGF1R kinase inhibitor A-928605
32. Utilization of 18 F-Fluorodeoxyglucose-Positron Emission Tomography To Understand the Mechanism of Nicotinamide Phosphoribosyltransferase Inhibitors In Vivo.
Catalog
Books, media, physical & digital resources
Discovery Service for Jio Institute Digital Library
For full access to our library's resources, please sign in.